SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to artificially boost its financial results. The litigation, filed in a Texas federal court, alleges that Nutex collaborated with third-party billing firm HaloMD to submit ineligible insurance claims, misleading shareholders and ...

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][10]. Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2]. - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract excessive reimbursements [2][4]. - The complaint asserts that Nutex's revenue model is unstable and that financial statements misrepresented the company's operations [3]. Group 2: Market Reaction - Following the release of a report by Blue Orca Capital accusing HaloMD of fraud, Nutex's stock dropped over 10%, indicating investor concern [4][5]. - After Nutex delayed its Form 10-Q submission, shares plummeted 16.39% the next day, closing at $92.91 [7]. Group 3: Financial Reporting Issues - The lawsuit highlights misrepresentation in Nutex's financial controls, particularly regarding the classification of stock-based compensation obligations [6]. - On August 21, Nutex disclosed that its Audit Committee found prior financial statements required restatement due to incorrect classification of obligations related to hospital development [8]. Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [10][11]. - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [12].